{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:eplerenone",
  "owner": "cardio",
  "kind": "drug",
  "slug": "eplerenone",
  "name": "Eplerenone",
  "aliases": [
    "Inspra"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "Eplerenone, sold as Inspra, is an aldosterone antagonist, a medicine taken by mouth. The US label read, for Inspra tablets, lists two uses in adults: improving survival in stable people who have symptomatic heart failure with reduced ejection fraction (40% or less) after a heart attack, and the treatment of high blood pressure to lower it.",
  "summary_technical": "RxNorm ingredient 298869; UNII 6995V82D0B. MeSH descriptor D000077545 is Eplerenone. Class: Aldosterone Antagonist (FDA established pharmacologic class, RxClass). The label read is the Viatris Specialty LLC label for Inspra tablets, application NDA021437, effective 2025-06-23 in openFDA. Generic eplerenone labels were not read. This page records label indications, the mechanism sentence and the class only: no trial result and no dose is given.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": null,
  "identifiers": [
    {
      "scheme": "rxnorm",
      "value": "298869",
      "normalized_value": "298869",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "unii",
      "value": "6995V82D0B",
      "normalized_value": "6995V82D0B",
      "match": "exact",
      "version": null,
      "label": null,
      "from_source": false
    },
    {
      "scheme": "mesh",
      "value": "D000077545",
      "normalized_value": "D000077545",
      "match": "exact",
      "version": "read 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "heart",
        "blood-vessels"
      ],
      "condition-area": [
        "heart-failure",
        "hypertension",
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "substance",
    "mechanism": "The label says eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone."
  },
  "content_digest": "4612b467615436888490472bfc6632488a260a40e454e5ad3a1a476556a66950",
  "review": {
    "content_digest": "4612b467615436888490472bfc6632488a260a40e454e5ad3a1a476556a66950",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [
    {
      "release_id": "a25293eeae6350fb",
      "id": "cardio:claim-fda-eplerenone-label-indications",
      "owner": "cardio",
      "subject_entity_id": "cardio:eplerenone",
      "category": "descriptive",
      "statement": "The US label of Inspra (eplerenone tablets, Viatris Specialty LLC, application NDA021437; the version dated 2025-06-23 in openFDA) describes eplerenone as an aldosterone antagonist. It lists improving survival of stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and the treatment of hypertension in adults, to lower blood pressure.",
      "context": {
        "id": "cardio:ctx-fda-inspra-label-us",
        "label": "Adults with heart failure with reduced ejection fraction after a heart attack, and adults with hypertension, as described in the US label of Inspra tablets",
        "recipient": "adult",
        "population": "Stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction, and adults with hypertension, as the indications section of the label states.",
        "care_setting": "Prescription medicine, as described in the US label",
        "geography": "United States (label of the US Food and Drug Administration)",
        "life_stage_note": "Adults, as the label states",
        "life_stage_terms": null,
        "gestational_age_min_days": null,
        "gestational_age_max_days": null,
        "gestational_age_basis": null,
        "postnatal_age_min_days": null,
        "postnatal_age_max_days": null,
        "gestational_age_status": null,
        "postnatal_age_status": null,
        "followup_description": "Not applicable (label statement)",
        "eligibility": {
          "inclusion": [
            "Stable adult patients with symptomatic heart failure with reduced ejection fraction (40% or less) after an acute myocardial infarction",
            "Adults with hypertension"
          ],
          "exclusion": []
        }
      },
      "evidence_stage": "not_applicable",
      "certainty": "not_assessed",
      "certainty_method": null,
      "limitations": "This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, warnings (including raised potassium), interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.",
      "editorial_state": "draft",
      "checked_at": "2026-11-18",
      "next_review_due": null,
      "valid_from": null,
      "valid_to": null,
      "citations": [
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE",
          "applicability_note": "Label passage quoted in the research quote table (LB-04).",
          "snapshot": {
            "id": "cardio:openfda-label-inspra-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90",
            "source_effective_date": "2025-06-23",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-inspra",
            "source_type": "regulator",
            "title": "openFDA drug label record for Inspra (eplerenone tablets), Viatris Specialty LLC label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221a52bedc-8e2c-4116-a296-a87770676b4a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1a52bedc-8e2c-4116-a296-a87770676b4a (manufacturer Viatris Specialty LLC, application NDA021437), returned on 2026-11-18. The label text is dated 2025-06-23 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-eplerenone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.1 Heart Failure Post-Myocardial Infarction",
          "applicability_note": "Label passage quoted in the research quote table (LB-05, LB-06).",
          "snapshot": {
            "id": "cardio:openfda-label-inspra-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90",
            "source_effective_date": "2025-06-23",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-inspra",
            "source_type": "regulator",
            "title": "openFDA drug label record for Inspra (eplerenone tablets), Viatris Specialty LLC label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221a52bedc-8e2c-4116-a296-a87770676b4a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1a52bedc-8e2c-4116-a296-a87770676b4a (manufacturer Viatris Specialty LLC, application NDA021437), returned on 2026-11-18. The label text is dated 2025-06-23 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-eplerenone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "supports",
          "locator": "results[0].indications_and_usage[0], 1.2 Hypertension",
          "applicability_note": "Label passage quoted in the research quote table (LB-07).",
          "snapshot": {
            "id": "cardio:openfda-label-inspra-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90",
            "source_effective_date": "2025-06-23",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-inspra",
            "source_type": "regulator",
            "title": "openFDA drug label record for Inspra (eplerenone tablets), Viatris Specialty LLC label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221a52bedc-8e2c-4116-a296-a87770676b4a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1a52bedc-8e2c-4116-a296-a87770676b4a (manufacturer Viatris Specialty LLC, application NDA021437), returned on 2026-11-18. The label text is dated 2025-06-23 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-eplerenone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        },
        {
          "evidence_role": "context",
          "locator": "results[0].effective_time",
          "applicability_note": "Effective date of the label text read, 20250623.",
          "snapshot": {
            "id": "cardio:openfda-label-inspra-2026-11-18",
            "retrieved_at": "2026-11-18T17:27:10Z",
            "content_hash": "5faf76d843730007ed843afc66f467edf02eeccc748524c7f0b7abcfb7138e90",
            "source_effective_date": "2025-06-23",
            "public_archive_url": null,
            "source_state": "current"
          },
          "source": {
            "id": "cardio:openfda-label-inspra",
            "source_type": "regulator",
            "title": "openFDA drug label record for Inspra (eplerenone tablets), Viatris Specialty LLC label: indications, mechanism, class",
            "canonical_url": "https://api.fda.gov/drug/label.json?search=set_id:%221a52bedc-8e2c-4116-a296-a87770676b4a%22&limit=1",
            "identifiers": [],
            "publication_date": null,
            "publisher": "U.S. Food and Drug Administration (openFDA)",
            "edition": "The openFDA drug label record for set id 1a52bedc-8e2c-4116-a296-a87770676b4a (manufacturer Viatris Specialty LLC, application NDA021437), returned on 2026-11-18. The label text is dated 2025-06-23 (effective_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.",
            "reuse_basis": "openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed at research/snapshots/w4k24-openfda-label-eplerenone.json.",
            "public_text": "quote",
            "replaced_by": null,
            "retirement_note": null
          }
        }
      ],
      "review": {
        "content_digest": "01ac1869b5a9a278fc48ddfeeae377ddf83e4917e7cb4d751807ffb915db61bc",
        "current": [],
        "conflicting": [],
        "stale": [],
        "inactive": []
      },
      "api_path": "api/v1/claims/cardio--claim-fda-eplerenone-label-indications.json"
    }
  ],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "subtype_of",
        "label": "Eplerenone is an aldosterone antagonist (FDA established pharmacologic class in RxClass)",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:mineralocorticoid-receptor-antagonists",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-298869-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[1].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists improving survival in stable adults with symptomatic heart failure with reduced ejection fraction after an acute myocardial infarction as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:hfref",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-eplerenone-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists heart failure after an acute myocardial infarction as the setting of its first indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "cardio:myocardial-infarction",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-eplerenone-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "evaluated_for",
        "label": "FDA label lists the treatment of hypertension in adults as an indication",
        "clinical_claim_not_fact": true,
        "family": "clinical",
        "other_entity_id": "core:hypertension",
        "other_entity_in_atlas": true,
        "claim_id": "cardio:claim-fda-eplerenone-label-indications",
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "The mineralocorticoid receptor antagonist class is one of the four classes of the heart failure regimen",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:hfref-four-medicine-regimen",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": []
  },
  "page_path": "drugs/eplerenone/",
  "context_path": "api/v1/context/cardio--eplerenone.md"
}
